Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Therapeutic Solutions International Inc TSOI

Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene... see more

Recent & Breaking News (OTCPK:TSOI)

Therapeutic Solutions International Files Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell(TM) Universal Donor Adult Stem Cells

Business Wire May 9, 2022

Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung Damage Using its JadiCell(TM) Universal Donor Stem Cell Drug

Business Wire May 2, 2022

Therapeutic Solutions International Identifies Novel Biological Pathway Utilized by its Phase III Adult Stem Cell Product JadiCell(TM) to Stimulate Healing of Injured Lung Tissue

Business Wire April 19, 2022

Therapeutic Solutions International Provides Correction Re Prior Release

Business Wire March 30, 2022

Therapeutic Solutions International Selects Premier Regenerative Medicine CRO Biorasi to Initiate and Run Phase III FDA Registration Clinical Trial for JadiCell(TM) Universal Donor Adult Stem Cell Product

Business Wire March 28, 2022

Therapeutic Solutions International Completes Purchase of FDA Phase III JadiCell Stem Cell Investigational New Drug Application from University of Miami

Business Wire March 25, 2022

Therapeutic Solutions International Granted Second United States Patent on QuadraMune® for Prevention, Inhibition, and Treatment of COVID-19

Business Wire March 10, 2022

Therapeutic Solutions International Announces ApoptoCyte Procedure for Enhancing Stem Cell Activity

Business Wire March 7, 2022

Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Preclinical Safety and Efficacy Data Using CampbellCell(TM) for Treatment of Schizophrenia

Business Wire February 14, 2022

Therapeutic Solutions International Announces Reduction of COVID-19 Associated Cognitive Decline by QuadraMune® Nutraceutical in Animal Model

Business Wire February 7, 2022

Therapeutic Solutions International Reports Positive Clinical Data on QuadraMune® Reduction of SARS-CoV-2 Spike Protein Induced Inflammation

Business Wire January 3, 2022

Therapeutic Solutions International Successfully Treats "No Option" Patients with its JadiCell(TM) Stem Cell Therapy While Advancing Preparations for Phase III COVID-19 Clinical Trial

Business Wire December 30, 2021

Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment

Business Wire December 28, 2021

Therapeutic Solutions International Announces Initiation of JadiCell(TM) Manufacturing Program to Address Upcoming FDA Phase III Trial and Emergency Use Requests

PR Newswire October 11, 2021

Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production

PR Newswire October 4, 2021

Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune(TM) Ingredients by Independent Universities Made After Patent Filing

PR Newswire September 27, 2021

Therapeutic Solutions International Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in COVID-19 Model

PR Newswire September 22, 2021

Therapeutic Solutions International Identifies and Files Patent on Combination Effects Between its Nutraceutical QuadraMune(TM) and Ivermectin in Animal Models of COVID-19 Pathology

PR Newswire September 16, 2021

Therapeutic Solutions International Successfully Treats Veteran Navy SEAL Suffering from Chronic Traumatic Encephalopathy with JadiCell(TM) Adult Stem Cells Under Right to Try Law

PR Newswire September 13, 2021

Therapeutic Solutions International Engages Venvalo Group to Oversee JadiCell COVID-19 Phase III Clinical Trial and Emergency Use Authorization (EUA) Process

PR Newswire September 10, 2021